



ADVISORY GROUP UPDATE

APRIL 2015

Welcome to the first update from the ECLIPSE research team.

This update includes:

- An overview of the project
- An outline of the purpose, membership and functioning of the advisory group
- An update on current progress and plans

### About the ECLIPSE study

ECLIPSE is a research project, funded by the National Institute for Healthcare Research (NIHR), to examine IV medication administration practices in UK hospitals. The project aims to identify key issues related to intravenous medication errors, to develop strategies to minimise the incidence of such errors, and to deliver recommendations for best practice in different situations. The first phase involves a national point prevalence study of the frequency and types of errors involving IV infusions. Phase two will involve an in-depth observational study to gain a rich and detailed understanding of the factors influencing practices. Finally, phase three will focus on developing and disseminating recommendations to inform future strategy in purchasing, deployment and use of IV medication technology.

For a more detailed account of the study you can find our protocol on the NIHR website at:

<http://www.nets.nihr.ac.uk/projects/hsdr/1220927>

### Purpose and Role of the ECLIPSE Advisory Group

The advisory group does not have formal terms of reference. The Group is intended to provide a forum for discussion regarding all aspects of ECLIPSE. Its general remit is to provide advice and guidance to support, inform and strengthen the project's research and dissemination activities. In particular, it is hoped the group will provide opportunities for:

- Sharing knowledge, views, experience and expertise.
- Advising the ECLIPSE team of any developments, issues or initiatives in the field that may be relevant to the project.
- Discussion of any difficulties encountered and potential solutions.
- Discussion and critical review of emerging findings and their implications.
- Advising on the strategic direction of the project in subsequent phases.
- Supporting dissemination activities and ensuring wide reach across all relevant sectors.
- Identifying any gaps and potential future research areas of interest.

The remit of the advisory group does not include formal oversight of project plans and progress. The ECLIPSE study benefits from a formal Study Steering Committee, appointed by the NIHR to oversee the progress of the study on behalf of the Project Sponsor and Project Funder. Rather, the purpose in setting up the ECLIPSE Advisory Group was to harness the skills and perspectives of a wide range of experts in the field in order to maximise the value and impact of the project.

## Membership of the ECLIPSE Advisory Group

The Advisory Group is composed of invited individuals who bring complementary specialist expertise from a range of organisations, roles and perspectives. Members include academics, clinicians, representatives from NHS trusts and professional organisations, and patient representatives, all with a particular interest or expertise in this research area. A full list of current members is provided below. Ann Jacklin has been appointed to chair this group.

Name	Affiliation
Pat Baird	Chair of the AAMI Foundation HSTI Infusion Device Steering Committee
Nick Barber	The Health Foundation
David Bates	Brigham & Women's Hospital, Boston MA, USA
John Byrne	National Association of Medical Device Educators and Trainers (NAMDET)
David Cousins	NHS England
Ann Jacklin (Chair)	Chair of the Centre for Medication Safety and Service Quality (CMSSQ), Imperial College Healthcare NHS Trust / UCL School of Pharmacy
Sue Keeling	Lead for MEDUSA national IV guide
Linda Murdoch	St George's University Hospitals NHS Foundation Trust
Steve Tomlin	Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust
John Trow	Patient representative
Carolyn Wheatley	Patient representative
David Upton	Sheffield Children's NHS Foundation Trust

## How the Advisory Group will operate

The intention is that advisory group meetings will be held to coincide with major project milestones. In between, the group will be kept informed of progress through periodic email updates. We propose to hold the first meeting of the advisory group in early 2016, at the conclusion of phase one of the project. This meeting will involve reflection on and discussion of the emerging findings from the point prevalence study.

The way in which the advisory group operates may vary according to the needs of the project over time. In the meantime we welcome any comments or suggestions from members related to the project.



## Further information about ECLIPSE

For further information and to keep up to date with the project visit our website at <http://www.eclipse.ac.uk> or follow us on twitter [@nihreclipse](https://twitter.com/nihreclipse)

## Progress and Plans

### ECLIPSE launch Sept 9th 2014

ECLIPSE was officially launched at an event at the UCL School of Pharmacy in September 2014. The launch featured an introduction to the project and a keynote talk delivered by Professor Nick Barber (Director of Research, Health Foundation). The event was attended by about 50 people and generated substantial interest. The launch provided an opportunity for representatives from NHS Trusts to ask questions about the project and express interest in taking part in the study.

### Plans for the next six months

- Continue to provide training for the point prevalence study data collectors.
- Complete point prevalence data gathering and analysis.
- Provide feedback of key findings to participating sites
- Prepare for ethical and NHS review for phase two.

### Progress in the last six months

- Ethical approval

The project has received NHS research ethics approval (NRES Committee South Central-Berkshire B; REC reference 14/SC/0290).

- Patient-public involvement (PPI) workshop

In October we held a first PPI workshop attended by nine patient representatives from England and Scotland. Participants shared their experiences of receiving IV medication and offered feedback on the patient information sheet. The Patient Information Sheet has since been edited and the amended version approved by the ethics committee. The discussions will also inform research questions in later phases of the study.

- Recruitment and site selection

About 18 trusts, representing 26 hospitals, expressed an interest in participating in this study and completed an initial survey about their current infusion devices and practices. After. We are keen to ensure that our sample represents a wide variety of different types of hospitals, devices and practices. Therefore, after reflecting on the survey data provided, we also approached a number of additional sites directly to invite them to participate. We have now invited a sample of 14 sites to participate.

- R&D approvals

Study wide governance checks have been completed and a financial agreement template agreed. Local approvals and access are currently being sought at all the recruited sites.

- Training

We have developed and begun delivering training to local data collectors for the phase one point prevalence study.

- Data collection and data entry

A data gathering protocol, and data collection and data entry forms used in a US point prevalence study, were made available to us. We have adapted and tested these to ensure they are appropriate in the UK context. We are now ready to begin data collection as and when local permissions are granted at each study site.